BlackRock Investment Management’s Soleno Therapeutics SLNO Stock Holding History

BlackRock Investment Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4	Closed	–	–	4111
2016 Q1	$0	Hold	4	–	–	﹤0.01%	4107
2015 Q4	$1K	Hold	4	–	–	﹤0.01%	4063
2015 Q3	$1K	Hold	4	–	–	﹤0.01%	4127
2015 Q2	$1K	Buy	+4	New	+$1.54K	﹤0.01%	4107

Other funds holding SLNO

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BlackRock Investment Management's SLNO Position: Q2 2016 in Review

BlackRock Investment Management sold out of Soleno Therapeutics (SLNO) in Q2 2016, closing a stake of 4 shares.

BlackRock Investment Management first reported a position in SLNO in Q2 2015 and held it in 4 quarters. The position peaked at $1K in Q4 2015. 7 funds tracked by Wall St. Rank hold SLNO as of Q2 2016.

BlackRock Investment Management reported no remaining Soleno Therapeutics position as of Q2 2016 after selling out during the quarter.
BlackRock Investment Management sold 4 Soleno Therapeutics shares in Q2 2016.
BlackRock Investment Management first reported a position in Soleno Therapeutics in Q2 2015 and held it in 4 quarters.
BlackRock Investment Management's Soleno Therapeutics position peaked at $1K in Q4 2015.
7 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.